Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Second Phase I Trial of Anti-Scarring Drug

Premium

RXi Pharmaceuticals this week announced that it has started a second double-blind phase I study of its RNAi-based anti-scarring compound RXI-109.

Three cohorts of three patients each will be enrolled to receive three intradermal injections of the drug over two weeks. Dose levels range from 2.5 mg to 7.5 mg per injection, and subjects will receive injections of RXI-109 and its delivery vehicle without the RNAi payload at small incisions on separate areas of their abdomen. 

Last month, RXi released final results from a single-dose phase I trial of the drug, showing that it was well tolerated in healthy volunteers scheduled to undergo abdominoplasty (GSN 11/15/2012).

“If we can continue at this pace, and assuming no unexpected hurdles, [we] should be able to move into [our] first phase II studies with RXI-109 in the second half of 2013,” RXi President and CEO Geert Cauwenbergh said in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.